Answers are grounded in this paper and cite their sources.
In practice, we see patients who strain to void, feel they empty incompletely, or rely on catheters. We label them with terms like “underactive bladder” or “detrusor underactivity” but do we really understand what we are diagnosing? A recent systematic review by LaFrance et al1 brings this lack of clarity into sharp focus. The authors sought to define the epidemiology and treatment outcomes of idiopathic underactive bladder (UAB) but encountered an unclear landscape. Across more than 1200 screened articles, only 24 met inclusion criteria. Excluded studies often failed to distinguish idiopathic UAB from neurogenic causes or bladder outlet obstruction. This is not just semantics, it shapes who we diagnose, how we treat, and the data we trust. Without standardized terms or International Classification of Diseases codes, especially for idiopathic UAB, patients disappear from data sets. Reported prevalence ranges from 2.2% to over 70% reflect this inconsistency. Urodynamics, our only formal tool, adds to the problem: it is overinclusive because of psychogenic inhibition of voiding and underutilized in real-world care, distorting prevalence at both ends. This matter has a downstream effect when considering treatment: The authors report a sacral neuromodulation (SNM) success rate of 46.8% (range: 43.0%-57.1%) for these patients. Although this rate may appear modest, it should not be dismissed, particularly in a condition with no alternative therapies. In selected patients, outcomes are often more favorable. For example, in Fowler syndrome, SNM response rates exceed 70%,2,3 illustrating that with the right patient phenotype, neuromodulation can offer clinically meaningful benefit. This is not a call to abandon these terms, but to use them with intention. We must stop conflating detrusor underactivity (a urodynamic observation) with UAB (a clinical syndrome) and both with urinary retention (a potentially shared end point). UAB is not rare. It is just poorly defined, inconsistently identified, and underrepresented in the literature. Until we align on what we are naming and what we are measuring, we will continue to talk past one another, and past the needs of our patients.
No takes yet. Share an insight, caveat, or question.
Anis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: